San Francisco-based Unlearn has devised a powerful way to apply AI to improve clinical trials. Using advanced biostatistics and machine learning, Unlearn creates “digital twins” of clinical trial participants, reducing the number of actual humans that need to be recruited for control arms. This makes clinical trials cheaper and faster to execute, ultimately enabling life-changing therapeutics to reach patients sooner.
Get our weekly email newsletter of curated insights and AI news.
© 2022 Radical Ventures Investments Inc.